Abstracts Archive - Page 22 of 2607 - ACR Meeting Abstracts

Abstract Number: 0310 • ACR Convergence 2025
Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
Annahita Keravala¹, Philip Conaghan², shanna jackson¹, sharmila Vijay¹, Thomas Chalberg³, Jeyanesh Tambiah⁴ and Laurie Halligan¹, ¹Genascence, Palo Alto, CA, ²University of Leeds, Leeds, United Kingdom, ³Genascence Corp, Palo Alto, CA, ⁴Genascence, San Diego, CA
Background/Purpose: IL-1 contributes significantly to osteoarthritis (OA) pathology, driving inflammation and cartilage degradation. Prior therapies targeting IL-1 have shown limited success due to inadequate drug…
Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 0212 • ACR Convergence 2025
Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Therapeutic decisions during pregnancy in women with autoimmune rheumatic diseases (ARDs) such as SLE, APS, RA, and Sjögren’s syndrome require a personalized approach due…
Abstract Number: 0203 • ACR Convergence 2025
Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Sung Ik Cho¹, Jin Kyun Park², Hee Won Cho³, Eun Young Lee⁴, Eun Bong Lee¹ and Jun Won Park¹, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, ³Seoul National University, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: Cytomegalovirus (CMV) infection is a well-recognized complication in immunocompromised individuals, yet there islimited evidence guiding surveillance strategies in patients with rheumatic diseases on immunosuppressants.…
Abstract Number: 0196 • ACR Convergence 2025
Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients
Steven Taylor¹ and Elena Weinstein², ¹University of Colorado, Denver, CO, ²University of Colorado, Englewood, CO
Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…
Abstract Number: 0314 • ACR Convergence 2025
What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
Anne-Christine Rat¹, LATOURTE Augustin², Maud Wieczorek³, Jérémie sellam⁴, willy Ngueyon Sime⁵, Jacques Pouchot⁶, Christian Roux⁷, Alain SARAUX⁸, Francis Guillemin⁹ and Joel Coste¹⁰, ¹Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France, ²Rheumatology Department, Lariboisiere Hospital, Paris, France, ³Lausanne Univserty, Lausanne, Switzerland, ⁴Saint-Antoine hospital, Assistance Publique – Hôpitaux de Paris, Paris, France, Sorbonne University, Paris, France, ⁵CIC, Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, Nancy, France, nNancy, France, ⁶HEGP hospital, Assistance Publique-Hopitaux de Paris,, Paris, France, ⁷CHU Nice, Nice, France, ⁸CHU Brest, Brest, France, ⁹CHU Nancy, Nancy, France, ¹⁰, Assistance Publique – Hôpitaux de Paris, Paris, France
Background/Purpose: Few studies have examined how the quality of life (QoL) evolves in patients with osteoarthritis (OA) before undergoing total hip or total knee replacement…
Abstract Number: 0289 • ACR Convergence 2025
Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Didem Saygin¹, Matthew Diller², Varsha Surampudi³, Mark Bodkin³, Payam Farhadi⁴, Adam Schiffenbauer⁵, Audrey Kessel³, Chris Mecoli⁶, Rohit Aggarwal⁷, Helene Alexanderson⁸, Michelle Best⁹, Olivier Benveniste¹⁰, Hector Chinoy¹¹, Brian Feldman¹², Linda Kobert¹³, Manuel Lubinus¹⁴, Liza McCann¹⁵, Chester V. Oddis¹⁶, Nicolino Ruperto¹⁷, Jens Schmidt¹⁸, Victoria Werth¹⁹, Christie Bartels²⁰, Hanna Kim²¹, Andrew Mammen²², Julie Paik²³, Ellen M. Werner¹³, Ingrid de Groot²⁴, Pedro Machado²⁵, Susan Kim²⁶, Tahseen Mozaffar²⁷, Adam M Huber²⁸, Angelo Ravelli²⁹, Richard Scheuermann² and Lisa Rider³⁰, ¹Rush University Medical Center, Chicago, IL, ²National Library of Medicine, National institutes of Health, Bethesda, MD, ³Social Scientific System Inc, a DLH holding company, Baltimore, MD, ⁴National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁵National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Cure JM Foundation, Lessburg, VA, ¹⁰Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Myositis Association, Columbia, MD, ¹⁴Myositis Support and Understanding, Lincoln, DE, ¹⁵Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ¹⁸Immanuel University Hospital Ruedersdorf, Brandenburg Medical School, Rudersdorf, Germany, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ²¹NIAMS, NIH, Bethesda, MD, ²²NIH, Bethesda, MD, ²³Johns Hopkins Rheumatology, Baltimore, MD, ²⁴The Myositis Association, Rotterdam, Netherlands, ²⁵University College London, London, United Kingdom, ²⁶UCSF Benioff Children's Hospital, San Francisco, CA, ²⁷University of California, Irvine, Orange, CA, ²⁸IWK Grace Health Centre, Halifax, NS, Canada, ²⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ³⁰National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Recent progress has been made in developing myositis outcome assessments, response and classification criteria, and consensus in the design and conduct of clinical trials…
Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Xiwei Yang¹, Shae Chambers², Aretha On¹, Hammad Ali², Touraj Khosravi³, Lais Lopes Almeida Gomes², Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…
Abstract Number: 0279 • ACR Convergence 2025
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Yoshiya Tanaka¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Kazuichi Okazaki⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, melissa rosen⁹, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone¹⁰, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Kansai Medical University Kori Hospital, Osaka, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 0271 • ACR Convergence 2025
Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review
Rafael Gálvez Sánchez¹, Fernando Lopez Gutierrez², Javier Loricera³, Pablo Martínez Calabuig⁴, Jorge Juan Fragío Gil⁵, Roxana González Mazario⁶, Cristina Hormigos Martin⁷, DALIFER FREITES⁸, Maria Rodriguez Laguna⁹, Patricia Moya Albarado¹⁰, Marta López i Gómez¹¹, Hector Corominas¹², Maite Silva-Diaz¹³, GUILLERMO GONZALEZ ARRIBAS¹⁴, Angel Garcia-Aparicio¹⁵, Judit Font-Urgelles¹⁶, Ivette Casafont-Solé¹⁶, elisabeth Castañeda¹⁷, Carolina Merino¹⁸, Raquel Zas¹⁹, Juan Molina-Collada²⁰, Sergio Rodríguez Montero²¹, Rafael B. Melero-González²², Eva Galíndez Agirregoikoa²³, Andrea Hernández²⁴, Lucia Pantoja²⁵, Ignacio Braña²⁶, Vega Jovaní²⁷, Elia Valls-Pascual²⁸, Natalia Mena Vázquez²⁹, Adela Gallego³⁰, Noelia Cabaleiro Raña³¹, Raul Veroz³², Mariano Andrés Collado³³, Santos Castañeda³⁴ and Ricardo Blanco³⁵, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Immunopathology Group -IDIVAL, Reumatología, Santander, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁵Hospital General Universitario, Valencia, Spain, ⁶Hospital General de Valencia, Valencia, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ¹⁴Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁵Hospital Universitario de Toledo, Toledo, Spain, ¹⁶Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁷Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, ¹⁸Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Spain, ²¹Hospital Universitario de Valme, Sevilla, Andalucia, Spain, ²²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ²³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ²⁴Hospital Universitario de Gran Canaria Dr Negrin, Palmas de Gran Canaria, Canarias, Spain, ²⁵Complejo Hospitalario Segovia, Segovia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ²⁷Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ²⁸Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ³⁰Complejo Hospitalario don Benito Villanueva, Badajoz, Spain, ³¹Hospital Universitario Montecelo, Rheumatology, Pontevedra, Galicia, Spain, ³²Hospital de Merida, Merida, Extremadura, Spain, ³³Hospital General Universitario de Alicante, Madrid, Comunidad Valenciana, Spain, ³⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory entity that can involve almost every organ, with characteristic histological features. Its pathogenesis remains poorly understood, clinical…
Abstract Number: 0205 • ACR Convergence 2025
Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Laura Mas Sanchez¹, ELENA GRAU GARCIA², Carlos Valera Ribera³, Pablo Muñoz-Martínez⁴, Daniel Ramos Castro⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Miguel Simeo Vinaixa⁹, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitari i Politecnic La Fe, València, Spain, ²HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario Doctor Peset, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: In 2023, Spain approved the inactivated varicella zoster virus (VZV) vaccine in individuals over 50 years of age with immunosuppressive conditions, including rheumatology patients…
Abstract Number: 0213 • ACR Convergence 2025
Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Braulio R. Avalos-Garcia², Andres M. Ortiz-Rios², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…
Abstract Number: 0220 • ACR Convergence 2025
National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
Alissa Becerril¹, Jing Li², Cherish Wilson³, Gary Tarasovsky⁴, Abimbola Fadairo-Azinge⁵, Mary Whooley⁴ and gabriela Schmajuk⁶, ¹UCSF, san francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴SFVA, San Francisco, ⁵UCSF, San Francisco, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Allopurinol can cause life-threatening severe cutaneous adverse reactions, especially in patients who carry the HLA-B58:01 allele. Because this allele is more common among Southeast…
Abstract Number: 0211 • ACR Convergence 2025
Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
Alexandra Do¹, Lisa Matsumoto¹, Cherish Wilson², Gary Tarasovsky³, gabriela Schmajuk⁴ and Jennifer Barton⁵, ¹Oregon Health and Science University, Portland, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
Abstract Number: 0190 • ACR Convergence 2025
Health literacy and comorbidity burden: a cluster analysis in a national cohort of people with inflammatory arthritis
Mrinalini Dey¹, James Galloway², Andrew Cope², MAYA BUCH³, Richard Osborne⁴, Sam Norton² and Elena Nikiphorou², ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²King's College London, London, United Kingdom, ³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ⁴La Trobe University, Melbourne, Victoria, Australia
Background/Purpose: Health literacy is a social determinant of health in people with chronic diseases, including inflammatory arthritis (IA). We aimed to assess the association between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].